Minims (Fluorescein Sodium, Lidocaine Hydrochloride)

Fluorescein sodium adheres to exposed proteins on a compromised corneal surface and emits a bright green fluorescence when illuminated with cobalt‑blue light. This contrast highlights epithelial defects, allowing clinicians to assess size, shape, and location of the injury accurately.

The specific dose and frequency of Minims are determined by the prescribing eye‑care professional based on the intended diagnostic or procedural use. The prescriber will decide the volume of drops and timing appropriate for each patient.

Safety data for Minims in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers should discuss individual circumstances with the patient before prescribing.

To request Minims, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Compared with alternatives such as rose bengal or lissamine green, fluorescein sodium provides rapid staining, strong fluorescence under blue light, and a well‑established safety profile. The addition of lidocaine in Minims offers the advantage of simultaneous anesthesia, reducing the need for a separate anesthetic drop.

Minims should be stored at room temperature, ideally below 25 °C, in its original sealed container. Protect the solution from direct light and moisture to maintain stability. Do not freeze the product, and keep it out of reach of children.

Minims is applied topically to the eye as a sterile drop. The prescriber will instruct the patient on the number of drops, the interval between applications, and any necessary precautions such as removing contact lenses before instillation.

Serious risks, although rare, include allergic reactions that may progress to anaphylaxis, corneal toxicity leading to persistent epithelial defects, and significant elevation of intra‑ocular pressure. Patients should be monitored for signs of severe irritation, swelling, or vision changes and seek immediate medical attention if they occur.

Minims should be avoided in individuals with known hypersensitivity to fluorescein, lidocaine, or any excipients in the formulation. Patients with active ocular infections, severe corneal disease, or uncontrolled intra‑ocular pressure should consult their eye‑care provider before use.